Adrenomedullin (AM) (22-52), human, is a NH2-terminal truncated forms of Adrenomedullin, which don’t possess the six-membered ring structure or retain the hypotensive and vasodilator activity[1, 2]. Adrenomedullin (AM) (22-52), human can be used as an antagonist of Adrenomedullin receptors[3]. Adrenomedullin (AM) (22-52), human antagonizes vasodilator responses to calcitonin gene-related peptide[4].
Adrenomedullin (AM) (22-52), human (10-7M; 60min) inhibited AM (10-7M; 30min) induced cAMP production in BACs[5]. Adrenomedullin (AM) (22-52), human (10-7M; 3 or 24h) abrogated the effect that Adrenomedullin (10-7M; 3 or 24h) evoked a small rise in adrenocorticotropic hormone (ACTH (10-8M; 3 or 24h)) stimulated corticosterone production in rat adrenocortical cells[6].
Adrenomedullin (AM) (22-52), human (250μg/rat/day; i.p. ; 2 weeks) reduced urinary protein excretion in the diabetic rats by some 40%[7]. Adrenomedullin (AM) (22-52), human (50μg/tumor; intratumoral injection; once a day for 10 days) significantly reduced the in vivo growth of the pancreatic cancer cell line, which were inoculated subcutaneously into the right flanks of severe combined immune deficiency (SCID) mice[8].
References:
[1] EGUCHI S, HIRATA Y, IWASAKI H, et al. Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells [J]. Endocrinology, 1994, 135(6): 2454-8.
[2] NOSSAMAN B D, FENG C J, KAYE A D, et al. Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats [J]. Am J Physiol, 1996, 270(5 Pt 1): L782-9.
[3] AKASHI E, NAGATA S, YAMASAKI M, et al. Activation of Calcitonin Gene-Related Peptide and Adrenomedullin Receptors by PEGylated Adrenomedullin [J]. Biol Pharm Bull, 2020, 43(11): 1799-803.
[4] CHAMPION H C, SANTIAGO J A, MURPHY W A, et al. Adrenomedullin-(22-52) antagonizes vasodilator responses to CGRP but not adrenomedullin in the cat [J]. Am J Physiol, 1997, 272(1 Pt 2): R234-42.
[5] VELARD F, CHATRON-COLLIET A, COME D, et al. Adrenomedullin and truncated peptide adrenomedullin(22-52) affect chondrocyte response to apoptotis in vitro: downregulation of FAS protects chondrocyte from cell death [J]. Sci Rep, 2020, 10(1): 16740.
[6] ZIOLKOWSKA A, BUDZYNSKA K, TREJTER M, et al. Effects of adrenomedullin and its fragment 22-52 on basal and ACTH-stimulated secretion of cultured rat adrenocortical cells [J]. Int J Mol Med, 2003, 11(5): 613-5.
[7] EL ETER E A, AL-MASRI A A. Adrenomedullin mediates early phase angiogenesis induced diabetic nephropathy in STZ diabetic rats [J]. Eur Rev Med Pharmacol Sci, 2014, 18(22): 3534-43.
[8] ISHIKAWA T, CHEN J, WANG J, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis [J]. Oncogene, 2003, 22(8): 1238-42.
Adrenomedullin (AM) (22-52), human是一种NH2末端截断形式的Adrenomedullin (AM)，不具有六元环结构，也不保有降血压和血管舒张活性[1,2]。Adrenomedullin (AM) (22-52), human可作为Adrenomedullin (AM) 受体的拮抗剂[3]。Adrenomedullin (AM) (22-52), human拮抗降钙素基因相关肽的血管舒张反应[4]。
Adrenomedullin (AM) (22-52), human（10-7M; 60min）可在关节软骨细胞中抑制Adrenomedullin (AM)（10-7M; 30min)诱导产生的cAMP[5]。Adrenomedullin (AM) (22-52), human （10-7M; 3 or 24h）消除大鼠肾上腺细胞内Adrenomedullin (AM)（10-7M; 3 or 24h）诱导ACTH（Adrenocorticotropic Hormone，促肾上腺皮质激素；10-8M; 3 or 24h）小幅升高刺激的皮质酮生成[6]。
使用Adrenomedullin (AM) (22-52), human（1μg/kg/day; i.p. ; 3 times a week for 8 weeks）处理糖尿病模型大鼠，Adrenomedullin (AM) (22-52), human下调糖尿病大鼠约40%的尿蛋白排泄量[7]。使用Adrenomedullin (AM) (22-52), human（25μg/kg; i.p. ; 4 day）处理右侧皮下接种的胰腺癌细胞系的SCID（severe combined immune deficiency，严重联合免疫缺陷）小鼠，Adrenomedullin (AM) (22-52), human显著抑制了肿瘤在SCID小鼠的体内生长[8]。